Summary
- As a leading wellness products seller with more than $2B in revenues, Nu Skin is generating attractive earnings, paying increasing dividends, and executing prudent share repurchases.
- Continued growth is expected due to its strong business moat in Asia.
- After tumbling from its peak share price in 2014, the stock is gaining momentum for past two years; yet valuation indicates it is undervalued with 19% upsides.
In 2012, Andrew Left (a notorious short seller with arguably unmatched accuracy) alleged that Nu Skin Enterprises (NYSE: NUS) - a firm that directly sells wellness products - was operating an illegal multi-level marketing ("MLM") business in China. Despite that shocking news, share price continues to levitate to its peak in H2 2013.
If you enjoy reading our research, be sure to sign up for our mailing list at Dr. Tran BioSci to get the latest market outperforming insights.
To access the complete article, please go to the premier investing research platform Seeking Alpha.
